ARDELYX, INC.

Lobbying for ARDELYX, INC.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Massachusetts · House · Senate · $580,000.00 expenses · posted Jan 19, 2026

Lobbying activity 1

Health Issues

Access to innovative kidney treatments, ESRD PPS, coverage of oral only medications for people with ESRD, innovation, Drug pricing, Medicare access to pharmaceuticals

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.